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Introduction: The hematologic indices of neutrophil-to-lymphocyte 
ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are correlated 
with clinical outcomes after stereotactic radiation.
Methods: We retrospectively evaluated the pretreatment NLR and 
PLR in patients treated with stereotactic radiation for early stage 
non–small-cell lung cancer at our institution. A total of 149 patients 
treated for non–small-cell lung cancer were identified, and 59 had 
stage I disease with neutrophil, platelet, and lymphocyte levels within 
a 3-month period before treatment. Receiver operating characteristic 
(ROC) analysis was performed to examine cutoff values for survival 
and nonlocal failure followed by Kaplan–Meier analysis for survival.
Results: With a median follow-up of 17 months, 28 deaths were 
observed, and the median overall survival for all patients was 43 months. 
Based on the ROC analysis, NLR and PLR cutoff values for further sur-
vival analysis were determined based on the ROC analysis to be 2.98 and 
146. The median overall survival was not reached for patients with low 
NLR or PLR but the survival was 23 months for patients with high NLR 
or PLR. There was no correlation between NLR and nonlocal failure, but 
on multivariate analysis PLR was found to be associated with freedom 
from nonlocal failure. Nonlocal failure rates were 11% for patients with 
PLR less than 250 and 58% for PLR greater than 250 (p < 0.001).
Conclusion: The pretreatment NLR and PLR represented significant 
prognostic indicators of survival in patients treated for early-stage 
non–small-cell lung carcinoma with stereotactic radiation. The PLR 
may be used as a prognostic indicator for nonlocal failure after ste-
reotactic radiation for early-stage lung cancer.
Key Words: Non–small-cell lung cancer, Stereotactic radiation, 
Early stage, Inflammation.
(J Thorac Oncol. 2015;10: 280–285)
An estimated 15% of patients with lung cancer are diag-nosed with clinically localized carcinoma of the lung.1 
The primary treatment for early-stage cancer is lobectomy. In 
those patients where lobectomy is not an option, such as for 
medically inoperable patients or for those unwilling to undergo 
surgery, stereotactic body radiation therapy, also known as 
stereotactic ablative radiotherapy (SABR), has shown efficacy 
with improved local control and survival outcomes relative to 
traditional radiation therapy.2
The cellular components of the host hematologic sys-
tem, including cells involved in hemostasis, inflammation, and 
immunity, may influence survival outcomes in patients with 
cancer.3 The neutrophil-to-lymphocyte ratio (NLR) is an easily 
derived marker of global inflammation with prognostic value for 
survival in patients with various solid tumors, with higher val-
ues associated with more aggressive cancers with poor progno-
sis.4–13 Thrombocytosis has also been negatively correlated with 
overall survival in patients with cancer, and investigators have 
also shown prognostic value in the platelet-to-lymphocyte ratio 
(PLR) for various malignancies.14–17 Both the NLR and PLR have 
also been shown to demonstrate prognostic utility for a variety of 
nonmalignant chronic medical conditions as well.18,19 Although 
neutrophil, lymphocyte, and platelet counts and ratios may sim-
ply be paraneoplastic surrogate markers for tumor-permissive 
or tumor-rejecting host states each of these cell types has also 
been shown to interact with and influence developing tumors in 
preclinical models. Thus, simple inexpensive-independent prog-
nostic factors derived from readily available laboratory values 
would have a practical impact on clinical oncology.
If the NLR and PLR showed prognostic value for patients 
undergoing radiation therapy for early-state lung cancer, this 
information may prove useful in selecting patients for adjuvant 
systemic therapy as a significant minority of patients with disease 
seemingly localized on initial staging will develop distant metas-
tases or regional failure. Use of adjuvant therapy in patients with 
early stage lung cancer, including those treated with SABR, is 
controversial, and the availability of simple biomarkers for dis-
ease dissemination would provide criteria for selecting patients 
for further treatment with systemic agents. Therefore, we evalu-
ated the association between the NLR and PLRT with survival 
and other outcomes in patients treated with stereotactic radiation 
for early stage non–small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
Patients treated at the University of Texas Southwestern 
(UTSW) for stage I NSCLC of the lung with SABR between 
January 1, 2006 and August 31, 2012 with recorded whole 
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blood counts within 3 months before radiation with biopsy-
proven stage I NSCLC were selected for study. Patients 
treated with stereotactic radiation were either not a candi-
date for lobectomy or elected not to have surgery. The ret-
rospective study was approved by the UTSW Institutional 
Review Board at the sponsoring institution.
For radiation treatments, patients were immobi-
lized with a large vacuum pillow inside either a commer-
cially available Elekta Stereotactic Body Frame (Elekta, 
Stockholm, Sweden) or a larger carbon fiber body frame. 
Tumor motion was assessed with fluoroscopy. If tumor 
motion was greater than 1 cm in any direction, respiratory 
coaching with abdominal compression was used to decrease 
tumor motion. Maximum intensity projection images from 
a four-dimensional computed tomography (CT) were reg-
istered with the simulation CT scan. The internal target 
volume was defined using maximum intensity projection 
images or a Boolean union of inspiration and expiration 
phases. The planning target volume was generated through 
a 0.5 cm expansion of the internal target volume in all 
directions. A treatment plan was generated using 7 to 13 
noncoplanar, nonopposing beams using the Pinnacle plan-
ning software (Phillips, Amsterdam, The Netherlands). 
Dosimetry required that 95% of the planning target vol-
ume received the prescription dose. Fractionation was 
based on tumor location, adjacent organ dose limits, and 
patient involvement in institutional and Radiation Therapy 
Oncology Group (RTOG) trial protocols.
Follow-up consisted of physical examination and CT 
scan every 3 months for the first year followed by continued 
exams with CT scans every 6 months. If there were suspicious 
findings including increase in consolidation near the treated site 
or the development of a new lung nodule or enlarging lymph 
node, a positron emission tomography–CT was performed. 
Fluorodeoxyglucose (FDG) avidity similar to the avidity at 
staging was considered evidence for recurrent disease. If there 
was still doubt, a biopsy was performed. Local failure was any 
recurrence within the same lobe of the lung that was treated. 
Nonlocal failure was a recurrence in any distant site or the 
regional lymph nodes including the hilum and mediastinum.
Patient characteristics were descriptively summa-
rized using means and standard deviations for continuous 
data and using frequencies for categorical data. Categorical 
data analyses were performed using a two-sided Fisher’s 
exact test. Multiple linear regression analyses were used to 
determine factors associated with NLR and PLR. Receiver 
operated characteristics (ROC) curves were constructed 
to determine cutoff values of NLR and PLR that yield the 
joint maximum sensitivity and specificity. Overall survival 
and nonlocal failure-free survival were calculated using the 
Kaplan–Meier method measured from the first day of treat-
ment. Comparisons of survival between groups were made 
using the log-rank test. Results were considered significant 
if the p value was less than 0.05. Cox regression analyses 
were used for univariate analyses. Stepwise Cox regression 
analyses were conducted to identify significant-independent 
factors associated with overall survival and freedom from 
nonlocal failure. SPSS version 21 was used for all statistical 
analyses (SPSS Inc.; Chicago, IL).
RESULTS
One hundred forty-nine patients were treated with 
SABR for lung cancer in the study period. Ninety-one of 
these patients had neutrophil, lymphocyte, and platelet counts 
in our records within 3 months before the initiation of radia-
tion therapy, but only 59 had biopsy-proven stage IA or IB 
NSCLC. Thirty-four patients had adenocarcinoma, 19 had 
squamous cell carcinoma, and six were not specified further 
than NSCLC. Patient characteristics and hematologic data are 
shown in Table 1. Tumors ranged in size from 1 to 5 cm, with 
a median value of 2.1 cm. Treatment was delivered in 1 to 8 
fractions over 1 to 22 days. Prescribed doses ranged from 34 
to 60 Gy (Table 2). Median follow-up for all patients was 17 
months. The 1- and 2-year overall survival was 80% and 74%, 
respectively.
Multiple linear regression analysis showed that age, gen-
der, location of the tumor and stage (IA or IB) were not sig-
nificantly associated with pretreatment NLR. However, larger 
tumor size (p = 0.010) was negatively associated with NLR. 
Multiple linear regression analysis showed that PLR was sig-
nificantly associated with gender (p = 0.030) and tumor size 
(p = 0.021). When PLR and NLR were compared with lin-
ear regression, there was a strong correlation (r = 0.772, p < 
0.001) between NLR and PLR.
ROC plots were generated to evaluate the relationship 
between overall survival and both NLR (area under the curve 
[AUC] = 0.678) and PLR (AUC = 0.681) (Fig. 1). The ROC cut-
off values for maximum joint sensitivity and specificity for pre-
dicting survival were 2.98 for NLR and 146 for PLR (Table 3). 
Patients were stratified based on these values, and survival was 
analyzed using the Kaplan–Meier method. Median overall sur-
vival for patients with a NLR less than 2.98 was not reached and 
for those with NLR greater than or equal to 2.98 was 23 months 
(p = 0.007 by log-rank test, 95% confidence interval [CI], 6–38 
months; Fig. 2A). Median overall survival for patients with 
PLR less than 146 was not reached, but for patients with values 
greater than or equal to 146 was 23 months (p = 0.003 by log-
rank test, CI, 10–35 months; Fig. 2B).
Univariate Cox regression analyses were performed 
using total dose, age, gender, NLR, PLR, histology, and tumor 
TABLE 1.  Patient Characteristics
Demographics Median (Range)
Patients 59
Men:Women 31:28
Age (years) 70 (48–89)
Central tumor location 14
Neutrophil (106 per ml) 4.8 (0.8–13.2)
Neutrophilia (>7.5 × 106 per ml) 5
Platelet (106 per ml) 230 (21–531)
Thrombocytosis (>400 × 106 per ml) 12
Lymphocyte (106 per ml) 1.5 (0.3–5.7)
Lymphocytopenia (<1 × 106 per ml) 12
NLR 2.8 (0.5–33.0)
PLR 151 (25–839)
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
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size as possible variables. When NLR and PLR were analyzed 
as continuous variables, overall survival was not significantly 
associated with either NLR or PLR. When NLR and PLR 
were coded as categorical variables with cutoffs of 2.98 and 
146, respectively, both NLR (p = 0.005) and PLR (p = 0.003) 
were significantly associated with overall survival. On step-
wise Cox regression analysis, only PLR coded as a categorical 
variable (hazard ratio [HR], 4.0; CI, 1.5–11.0; p = 0.006) was 
significantly associated with overall survival likely because 
PLR and NLR were previously found to be correlated. When 
examining the results based on the Charleston comorbidity 
index (CCI), the CCI was not associated with overall survival 
on univariate or multivariate analysis.
Patterns of tumor failure in the patients were also 
assessed. Two patients had a local failure, along with 12 
nonlocal failures. Both of the patients with local failures had 
NLR and PLR below the cutoff threshold used in survival 
analysis. Further analysis of local failure was not undertaken 
as a result of the low frequency of this event. A separate ROC 
analysis was performed to assess the best cutoff points for 
nonlocal failure for both NLR and PLR (Fig. 3A). The 1- and 
TABLE 2.  Treatment Characteristics Including Number of 
Fractions, Total Dose, and the Number of Patients Treated 
with Each Number of Fractions
Fractions Median Dose Range Patients
1 34 34 3
3 54 52.5–60 33
4 48 1
5 60 45–60 22
Stage
  IA 54 34–64 43
  IB 54 34–60 16
Distribution of patients by stage with median dose and dose range.
FIGURE 1.  ROC curve for NLR and PLR based on overall sur-
vival. ROC, receiver operating characteristics; NLR, neutro-
phil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
TABLE 3.  Distribution of Cases Based on ROC Cutoffs
NLR PLR
<2.98 >2.98 <146 >146 <250 >250
Alive 24 13 23 14 33 4
Deceased 7 15 5 17 14 8
No failure 25 20 23 22 40 5
Local failure 2 0 2 0 2 0
Nonlocal failure 4 8 3 9 5 7
ROC, receiver operating characteristics.
FIGURE 2.  Survival in early stage patients. A, Survival based 
on NLR. Solid blue: NLR less than 2.98; dashed green: NLR 
greater than 2.98. B, Survival based on PLR. Solid blue: PLR 
less than 146; dashed green: PLR greater than or equal to 
146. NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-
lymphocyte ratio.
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2-year rates of freedom from development of nonlocal fail-
ure were 86 and 74%, respectively. There was no significant 
cutoff point observed for NLR (AUC = 0.635; p = 0.15), but 
a PLR cutoff of 250 was found to maximize the sensitivity 
and specificity (AUC = 0.720; p = 0.02) (Table 3). When the 
patients were divided based on the 250 cutoff for PLR, there 
were 47 patients with PLR less than 250 with five nonlocal 
failures and 12 patients with PLR greater than or equal to 
250 with seven nonlocal failures. In patients with PLR less 
than 250, three failures were in different lobes of the lung and 
three were in the hilum or mediastinum. In patients with PLR 
greater than 250, two failures were in different lobes of the 
lung, four were in the hilum or mediastinum, and one was in 
the brain (Table 4).
Patients were stratified for Kaplan–Meier analysis 
based on PLR greater than or less than 250 (Fig. 3B). Median 
nonlocal failure-free survival for patients with PLR greater 
than or equal to 250 was 10.5 months (CI, 9.2–11.8 months, p 
< 0.001). The median nonlocal failure-free survival for those 
with PLR less than 250 was not reached. Univariate Cox 
regression analyses for development of nonlocal failure were 
performed using dose, age, gender, NLR, PLR, and tumor 
size as possible variables. When NLR and PLR were analyzed 
as continuous variables, freedom from nonlocal failure was 
not significantly associated with PLR (p = 0.133) or NLR 
(p = 0.937), but it was associated with increasing tumor size 
(HR, 1.73; CI, 1.02–2.96; p = 0.044). When coded as a binary 
variable with cutoff of 250, PLR (p < 0.001) was significantly 
associated with development of nonlocal failure along with 
tumor size (p = 0.003). On stepwise Cox regression analy-
ses, PLR as a binary variable (HR, 99.7; CI, 10.3–962; p < 
0.001), tumor size (HR, 2.45; CI, 1.42–4.25; p = 0.001), and 
age (HR, 0.92; CI, 0.85–0.99; p = 0.020) were significantly 
associated with freedom from nonlocal failure. When examin-
ing the results based on the CCI, the CCI was not associated 
with nonlocal failure-free survival on univariate or multivari-
ate analysis.
DISCUSSION
The link between inflammation, particularly chronic 
inflammation, and cancer progression has been known for 
over a century.3 Chronic inflammation has been shown to be 
associated with the induction of lung cancer and cancer in 
other organs.20 Chronic inflammation is associated with sup-
pression of anti-tumor immune responses and a proangiogenic 
“wound healing” environment that favors tumor progression. 
Cytokines are a key component of the inflammatory process, 
and their expression can lead to alterations in the levels of lym-
phocytes, neutrophils, and platelets.21 Moreover, lymphocytes, 
neutrophils, and platelets have all individually been implicated 
in modulation of tumor growth, in both negative and positive 
associations. Circulating T lymphocytes with specificity for 
tumor-associated antigens lead to tumor rejection, whereas 
other populations of lymphocytes such as regulatory T cells 
may suppress antitumor cytotoxic lymphocytes.22
Neutrophils have also been shown to have both tumor-
promoting and tumor-suppressing abilities. In a preclinical 
model, Fridlender et al.23 showed that neutrophils exhibit plas-
ticity in their anti- and pro-tumor effects under the control of 
transforming growth factor-β. Other investigators have shown 
that inhibiting neutrophil infiltration of tumors slowed tumor 
growth.24 Neutrophils can inhibit the immune response in lung 
cancer by tumor-induced secretion of arginase.25
Platelets facilitate circulation of tumor cells and may play 
a role in homing of circulating tumor cells to distant organs.26 
FIGURE 3.  ROC curve for NLR and PLR based on development 
of nonlocal failure. A, ROC curve for nonlocal failure. Solid blue: 
NLR; dashed green: PLR. B, Kaplan–Meier survival of patients 
with or without PLR greater than or equal to 250. Solid blue: 
PLR less than 250; dashed green: PLR greater than or equal to 
250. ROC, receiver operating characteristics; NLR, neutrophil-to-
lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
TABLE 4.  Patterns of Failure
Lung
Hilum or 
Mediastinum Brain
<250 (N = 47) 3 2 0
>250 (N = 12) 2 4 1
The location of distant failure based on platelet-to-lymphocyte ratio.
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Previous studies demonstrated that depletion of platelets inhib-
ited metastatic potential, and the reconstitution of platelet lev-
els restored metastatic potential.27,28 Platelet interactions with 
tumor cells lead to rolling and tethering of tumor cell aggre-
gates, leading to extravasation through the endothelial wall and 
immune protection.26,29 Platelets have been shown to promote 
the spread of tumors through multiple mechanisms including 
selectin and integrin interactions with tumor cells.30
An outstanding dilemma in the treatment of early-stage 
lung cancer is selection of patients for the use of adjuvant sys-
temic therapy. In a recently published RTOG phase II eval-
uation of SABR for treatment of early stage lung cancer in 
medically inoperable patients, despite excellent local tumor 
control rates approximately 20% of patients developed distant 
metastatic disease by 3 years.2 A simple prognostic biomarker 
derived from the complete blood count such as the PLR may 
find use in selecting which subset of patients with clinically 
staged localized disease would benefit from adjuvant systemic 
treatment. As SABR is associated with a rapid treatment 
course typically without significant acute toxicities, chemo-
therapy can likely be seamlessly integrated into sequential 
treatment plans for these patients. In our analysis, we did not 
pursue biomarkers for local treatment failure as the rate of 
local recurrence was low.
Sarraf et al.9 recently reported on the NLR as a prog-
nostic biomarker in patients with early stage NSCLC under-
going surgery. As tumor-ablating treatments, surgery and 
SABR differ in many respects and thus may interact with and 
influence the host inflammatory state in different ways; as a 
result, it could not be clear before our study if the NLR would 
have the same prognostic status as it does in surgical patients. 
Interestingly, although increased NLR was associated with 
poor overall survival in our analysis, only the PLR was asso-
ciated with an increased risk of developing nonlocal failure. 
This finding may be related to the fact that patients treated 
in our study typically had significant medical comorbidities 
(precluding surgical intervention). Elevated NLR has previ-
ously been associated with worse outcomes in patients with 
serious chronic but nonmalignant medical conditions such as 
renal and cardiac disease.18,19 Many of the patient deaths in 
our study were related to these comorbidities as opposed to 
cancer-related death, but the Charleston comorbidity index 
was not related to either overall survival or nonlocal failure.
Our study is limited by its relatively small size and our 
findings need confirmation in larger series before their broad 
applicability in clinical decision-making for patients. Other 
studies examining trends in complete blood count (CBC) 
markers and response to therapy have been done in surgical 
and chemotherapy series. These modalities require a CBC 
within 1 week to 1 month before treatment. Because this is 
not always done routinely before SABR, the CBC in this study 
was up to 3 months before the initiation of treatment, which 
makes it more difficult to compare the results of this study 
to those of other studies. Because the PLR was predictive of 
development of metastases as a dichotomous variable, it could 
be examined in future prospective studies for its prognostic 
value, and these prospective studies should have CBCs closer 
to the time of treatment initiation. Further study of acute and 
chronic effects of SABR on hematologic parameters is also 
needed. High-dose radiation may also modulate neutrophil 
phenotype, altering the balance of pro- and antitumor neutro-
phils.31 Because NLR was associated with OS but not nonlo-
cal failure, further study may find that PLR is the dominant 
factor relating SABR with nonlocal failure or overall survival.
Overall, this is, to the best of our knowledge, the first 
study examining the association among stereotactic radia-
tion, hematologic variables, and survival and metastasis out-
comes in patients with stage I NSCLC and NLR or PLR. We 
observed worse outcomes in patients with an elevated NLR or 
PLR in early stage patients. An elevated PLR was also associ-
ated with an increased risk of nonlocal failure. The NLR and 
PLR can be used as a prognostic tool for patients with early 
stage disease. Further research should be done to examine 
the correlation between radiation treatments and the inflam-
matory response both pretherapy and posttherapy to further 
optimize treatment strategies.
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